BRCA遺伝子変異陽性卵巣がんの一次治療におけるPARP阻害薬オラパリブ(LYNPARZA®)、第Ⅲ相試験SOLO-1でPFS延長【米・Merck】

LYNPARZA® (olaparib) Significantly Delays Disease Progression in Phase 3 First-Line SOLO-1 Trial for Ovarian Cancer

 

 

 

コメント

Leave a comment

Your email address will not be published.


*